5-year follow up for 72 metastatic melanoma patients treated with eltrapuldencel-T (CLBS20) vaccine.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 3090)Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-05-31 / Oncoimmunology 2016 Jul;5(7):e1191732T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-04-11 / Cancer Res. 2016 06;76(12):3496-506Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-02-10 / Cancer Immunol. Immunother. 2016 Mar;65(3):327-39Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-02-01 / Melanoma Res. 2016 Feb;26(1):1-11Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2015-12-28 / Clin. Cancer Res. 2016 05;22(9):2155-66Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-6Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2015-09-01 / PLoS ONE 2015;10(9):e0136911Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial).
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr TPS9082)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution